EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity

Xi Wang, Liu Yang, Yuhao Hou, Guanyu Wang, Yu Ding, Yu Zhang, Shuyu Wang, Zhangyong Hong iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177716 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Xi Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China. Hauptthemen laut MEDLINE: Interleukin-12, Prodrugs, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Tianjin, Natural Science Foundation of Tianjin, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-12 (IL-12) potently promotes the recruitment and activation of immune cells within the tumor microenvironment (TME), highlighting its immense potential for cancer therapy. However, its dose-limiting systemic toxicity and short half-life severely hinder its clinical translation. Here, we design a tumor-conditionally activated IL-12 prodrug termed αHSA-proIL-12. This engineered molecule integrates a cleavable albumin-binding nanobody (αHSA) domain to extend the half-life and enhance tumor targeting alongside a masking domain that occludes the IL-12 receptor-binding site to prevent nonspecific activation. This construct undergoes selective cleavage by matrix metalloproteinases (MMPs) that are highly expressed in the TME to release highly penetrant, free, low-molecular-weight IL-12 locally. This tumor-restricted activation process directly facilitates the selective recruitment and activation of tumor-infiltrating lymphocytes (TILs). The intravenous administration of an extremely low dose of 108 pmol per dose of αHSA-proIL-12 completely cleared MC38 tumors without inducing systemic toxicity. The maximum tolerated dose of this molecule exceeded 2 nmol, yielding a remarkably wide therapeutic index >18.5. Mechanistically, αHSA-proIL-12 effectively reprogrammed the immunosuppressive TME by expanding the numbers of effector CD8+ T cells and natural killer cells while upregulating IFN-γ expression and significantly reducing the proportion of regulatory T cells. This immunological remodeling has the potential to convert “cold” tumors into “hot” tumors. Notably, this treatment achieved complete regression and durable immunity in a subset of mice with multiple refractory immune-cold tumors, including Panc02 pancreatic cancer, 4T1 triple-negative breast cancer, and B16F10 melanoma, when administered as a monotherapy or in combination with PD-L1 blockade. Furthermore, when combined with surgery, αHSA-proIL-12 effectively prevented the postoperative recurrence and distant metastasis of advanced 4T1 tumors. This modular platform provides a clinically promising strategy to overcome the toxicity bottleneck of cytokines and substantially advances the development of combination cancer immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-12ProdrugsAntineoplastic AgentsAnimalsMiceFemaleTumor MicroenvironmentHumansLymphocytes, Tumor-InfiltratingCell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

cytokinehalf-lifeimmune checkpoint blockade (ICB)immunotherapyinterleukin-12prodrugsurgery

Substanzen

Interleukin-12ProdrugsAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China.
  • Nankai International Advanced Research Institute (ShenzhenFutian), Shenzhen 518045, China.

ORCID-Profile: Zhangyong Hong

Förderung

  • Natural Science Foundation of Tianjin
  • Natural Science Foundation of Tianjin, China

Zitieren

APA

Wang, X., Yang, L., Hou, Y., Wang, G., Ding, Y., Zhang, Y., Wang, S., & Hong, Z. (2026). αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177716

Vancouver

Wang X, Yang L, Hou Y, Wang G, Ding Y, Zhang Y, et al. αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177716

BibTeX
@article{Wang2026,
  author = {Wang, Xi and Yang, Liu and Hou, Yuhao and Wang, Guanyu and Ding, Yu and Zhang, Yu and Wang, Shuyu and Hong, Zhangyong},
  title = {αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177716}
}
Kostenlos starten →